Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Covestor Ltd

Covestor Ltd cut its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 91.2% in the 3rd quarter, Holdings Channel reports. The fund owned 357 shares of the medical equipment provider’s stock after selling 3,704 shares during the period. Covestor Ltd’s holdings in Lantheus were worth $39,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Signaturefd LLC lifted its position in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 208 shares during the last quarter. UMB Bank n.a. lifted its holdings in Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 126 shares during the last quarter. Kathleen S. Wright Associates Inc. bought a new position in Lantheus in the third quarter worth about $51,000. Finally, Nkcfo LLC bought a new position in Lantheus in the second quarter worth about $47,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Stock Performance

Lantheus stock opened at $76.83 on Friday. The company has a 50 day moving average price of $104.95 and a 200 day moving average price of $96.24. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89. The firm has a market capitalization of $5.34 billion, a price-to-earnings ratio of 12.78 and a beta of 0.51.

Analysts Set New Price Targets

LNTH has been the topic of several analyst reports. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Friday, November 8th. JMP Securities decreased their price target on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. Truist Financial restated a “buy” rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. B. Riley lifted their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Finally, Redburn Atlantic began coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $122.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.